125. Rimbu M.C., Popescu L., Mihaila M., Sandulovici R.C., Cord D., Mihailescu C.M., Galanu M.L., Panuroiu M., Manea C.E., Boldeiu A., Brincoveanu O., Savin M., Grigoroiu A., Ungureanu F.D., Amzoiu E., Popescu M., Trua E. Synergistic effects of green nanoparticles on antitumor drug efficacy in hepatocellular cancer. Biomedicines Mar 5 2025, 13, doi:10.3390/biomedicines13030641. IF=3.9; Q2
124. Ion G., Bostan M., Hardman W.E., Mcfarland M.P., Bleotu C., Radu N., Diaconu C.C., Mihaila M., Caramihai M.D., Hotnog C.M. Nutrients lowering obesity-linked chemokines blamable for metastasis. International Journal Of Molecular Sciences Mar 2025, 26, doi:10.3390/ijms26052275. IF=4.9; Q1
123. Marian T., Radu N., Voicescu M., Nistor C.L., Pirvu L.C., Mihaila M., Bostan M. Preliminary biological assessments of some algae basis biomaterials. Journal Of Marine Science And Engineering Feb 2025, 13, doi:10.3390/jmse13020318. IF=3.6; Q2
122. Tincu R., Mihaila M., Bostan M., Istrati D., Badea N., Lacatusu I. Hybrid albumin-decorated lipid-nanocarrier-mediated delivery of polyphenol-rich Sambucus nigra L. In a potential multiple antitumoural therapy. International Journal Of Molecular Sciences Oct. 2024, 25, doi:10.3390/ijms252011206. IF=4.9; Q1
121. Fudulu A., Bostan M., Iancu I.V., Plesa A., Albulescu A., Stoian I.L., Socolov D.G., Anton G., Botezatu A. Assessing the methylation status of two potential key factors involved in cervical oncogenesis. Reports Sep 2024, 7, doi:10.3390/reports7030071. IF=0.8; Q3
120. Cocos F.I., Anuta V., Popa L., Ghica M.V., Nica M.A., Mihaila M., Fierascu R.C., Trica B., Nicolae C.A., Dinu-Pîrvu C.E. Development and evaluation of docetaxel-loaded nanostructured lipid carriers for skin cancer therapy. Pharmaceutics Jul 2024, 16, doi:10.3390/pharmaceutics16070960. IF=4.9; Q1
119. Radu C., Olteanu A.A., Arama C.C., Mihaila M., Uivarosi V. Investigating the effect of cyclodextrin nanosponges and cyclodextrin-based hydrophilic polymers on the chemical pharmaceutical and toxicological profile of AI(III) and Ga(III) complexes with 5-hydroxyflavone. Applied Sciences-Basel Jul 2024, 14, doi:10.3390/app14135441. IF=2.5; Q2
118. Bostan I.S., Mihaila M., Roman V., Radu N., Neagu M.T., Bostan M., Mehedintu C. Landscape of endometrial cancer: Molecular mechanisms, biomarkers, and target therapy. Cancers Jun 2024, 16, doi:10.3390/cancers16112027. IF=4.5; Q1
117. Fudulu A., Diaconu C.C., Iancu I.V., Plesa A., Albulescu A., Bostan M., Socolov D.G., Stoian I.L., Balan R., Anton G., Botezatu A. Exploring the role of E6 and E7 oncoproteins in cervical oncogenesis through MBD2/3-NuRD complex chromatin remodeling. Genes May 2024, 15, doi:10.3390/genes15050560. IF=2.8; Q2
116. Ivan I.M., Olaru O.T., Popovici V., Chitescu C.L., Popescu L., Luta E.A., Ilie E.I., Brasoveanu L.I., Hotnog C.M., Nitulescu G.M., Boscencu R., Gîrd C.E. Antioxidant and cytotoxic properties of Berberis vulgaris (L.) stem bark dry extract. Molecules May 2024, 29, doi:10.3390/molecules29092053. IF=4.2; Q2
115. Campanella A., Capasso A., Heltai S., Taccetti C., Albi E., Herishanu Y., Haggenburg S., Chatzikonstantinou T., Doubek M., Kättström M., Giannopoulos K., Simkovic M., Moreno C., Massaia M., Bumbea H., Alshemmari S., Ranghetti P., Perotta E., Martini F., Sant’antonio E., Colia M., Combi C., Levi S., Kater A.P., Hazenberg M., Nijhof I.S., Hofsink Q., Demosthenous C., Kotaskova J., Zaleska J., Vrbacky F., Raya A.M., Bisogno D., Tripoli I.E., Popov V.M., Roman V., Stavroyianni N., Karypidou M., Scarano E., Locatelli M., Frenquelli M., Scarfò L., Stamatopoulos K., Ghia P. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European research initiative on CLL. American Journal of Hematology Apr 2024, 99, 745-750, doi:10.1002/ajh.27218. IF=10.1; Q1
114. Ivan I.M., Popovici V., Chitescu C.L., Popescu L., Luta E.A., Ilie E.I., Brasoveanu L.I., Hotnog C.M., Olaru O.T., Nitulescu G.M., Boscencu R., Gird C.E. Phytochemical profile, antioxidant and cytotoxic potential of Capsicum annuum (L.) dry hydro-ethanolic extract. Pharmaceutics Feb 2024, 16, doi:10.3390/pharmaceutics16020245. IF=4.9; Q1
113. Stecoza C.E., Nitulescu G.M., Draghici C., Caproiu M.T., Hanganu A., Olaru O.T., Mihai D.P., Bostan M., Mihaila M. Synthesis of 1,3,4-thiadiazole derivatives and their anticancer evaluation. International Journal of Molecular Sciences Dec 2023, 24, doi:10.3390/ijms242417476. IF=4.9; Q1
112. Roman V., Mihaila M., Radu N., Marineata S., Diaconu C.C., Bostan M. Cell culture model evolution and its impact on improving therapy efficiency in lung cancer. Cancers Oct 2023, 15, doi:10.3390/cancers15204996. IF=4.5; Q1
111. Ivan B.C., Barbuceanu S.F., Hotnog C.M., Olaru O.T., Anghel A.I., Ancuceanu R.V., Mihaila M.A., Brasoveanu L.I., Shova S., Draghici C., Nitulescu G.M., Dumitrascu F. Synthesis, characterization and cytotoxic evaluation of new pyrrolo 1,2-b pyridazines obtained via mesoionic oxazolo-pyridazinones. International Journal of Molecular Sciences Jul 2023, 24, doi:10.3390/ijms241411642. IF=4.9; Q1
110. Bolovan L.M., Ceausu M., Stanciu A.E., Panait M.E., Busca A., Hotnog C.M., Bleotu C., Gales L.N., Georgescu M.T., Prunoiu V.M., Brasoveanu L.I., Voinea S.C. Correlation studies between S100 protein level and soluble MIA or tissue melanA and gp100 (hmb45) expression in cutaneous melanoma. Journal of Personalized Medicine Jun 2023, 13, doi:10.3390/jpm13060898. IF=3.0; Q2
109. Iordache T.A., Badea N., Mihaila M., Crisan S., Pop A.L., Lacatusu I. Polygonum cuspidatum loaded nanostructured lipid carriers for dual inhibition of TNF-α- and IL-6 cytokines and free radical species. Materials May 2023, 16, doi:10.3390/ma16093492. IF=3.1; Q3
108. Tincu R., Mihaila M., Bostan M., Teodorescu F., Istrati D., Badea N., Lacatusu I. Novel bovine serum albumin-decorated-nanostructured lipid carriers able to modulate apoptosis and cell-cycle response in ovarian, breast, and colon tumoral cells. Pharmaceutics Apr 2023, 15, doi:10.3390/pharmaceutics15041125. IF=4.9; Q1
107. Babeanu N., Radu N., Enascuta C.E., Alexandrescu E., Ganciarov M., Mohammed M.S.O., Suica-Bunghez I.R., Senin R., Ursu M., Bostan M. Obtaining and characterizing composite biomaterials of animal resources with potential applications in regenerative medicine. Polymers Sep 2022, 14, doi:10.3390/polym14173544. IF=5.0; Q1
106. Maciuca A.M., Munteanu A.C., Mihaila M., Badea M., Olar R., Nitulescu G.M., Munteanu C.V.A., Uivarosi V. A study on repositioning nalidixic acid via lanthanide complexation: Synthesis, characterization, cytotoxicity and DNA/protein binding studies. Pharmaceuticals Aug 2022, 15, doi:10.3390/ph15081010. IF=4.6; Q2
105. Ivan B.C., Barbuceanu S.F., Hotnog C.M., Anghel A.I., Ancuceanu R.V., Mihaila M.A., Brasoveanu L.I., Shova S., Draghici C., Olaru O.T., Nitulescu G.M., Dinu M., Dumitrascu F. New pyrrole derivatives as promising biological agents: Design, synthesis, characterization, in silico, and cytotoxicity evaluation. International Journal of Molecular Sciences Aug 2022, 23, doi:10.3390/ijms23168854. IF=5.6; Q1
104. Zaharie M.G.O., Radu N., Pirvu L., Bostan M., Voicescu M., Begea M., Constantin M., Voaides C., Babeanu N., Roman V. Studies regarding the pharmaceutical potential of derivative products from plantain. Plants-Basel Jul 2022, 11, doi:10.3390/plants11141827. IF=4.5; Q1
103. Botezatu A., Fudulu A., Iancu I.V., Bostan M., Mihaila M., Albulescu A., Diaconu C.C., Anton G., Plesa A. Assessment of HPV16 viral oncogenes’ role in genome-wide pattern deposition of MDB2/3 components of NURD nucleosome remodeling complex. Febs Open Bio Jul 2022, 12, 164-164. IF=2.6; Q4
102. Albulescu A., Fudulu A., Botezatu A., Iancu I.V., Plesa A., Brasoveanu L.I. Long noncoding RNA profile in neuroblastoma and glioblastoma. Febs Open Bio Jul 2022, 12, 83-84. IF=2.6; Q4
101. Botezatu A., Plesa A., Iancu I.V., Bostan M., Mihaila M., Albulescu A., Fudulu A., Diaconu C.C., Anton G. E6 and E7 HPV16 oncogenes influence gene transcription through the genome-wide pattern deposition of MDB2, 3 components of NURD nucleosome remodeling complex. In Proceedings of the EUROPEAN JOURNAL OF HUMAN GENETICS, 2022; pp. 542-542.
100. Iordache T.A., Badea N., Mihaila M., Crisan S., Pop A.L., Lacatusu I. Challenges in coopted hydrophilic and lipophilic herbal bioactives in the same nanostructured carriers for effective bioavailability and anti-inflammatory action. Nanomaterials Nov 2021, 11, doi:10.3390/nano11113035. IF=5.719; Q1
99. Ion G., Akinsete J.A., Witte T.R., Bostan M., Hardman W.E. Maternal fish oil consumption has a negative impact on mammary gland tumorigenesis in c3(1) tag mice offspring. European Journal of Nutrition Oct 2021, 60, 3771-3781, doi:10.1007/s00394-021-02546-8.IF=4.865; Q2
98. Dumitru M., Mihaila M., Hotnog C.M., Panait M.E., Vasilescu M.M., Hortopan M.G., Brasoveanu L.I. Her2 expression in primary bladder tumors and paired regional lymph nodes: Relationship to cell cycle profile. Annals of Oncology Oct 2021, 32, S1369-S1370, doi:10.1016/j.annonc.2021.08.2076. IF=51.769; Q1
97. Mihaila M., Hotnog C.M., Bostan M., Munteanu A.C., Vacaroiu I.A., Brasoveanu L.I., Uivarosi V. Anticancer activity of some ruthenium(III) complexes with quinolone antibiotics: In vitro cytotoxicity, cell cycle modulation, and apoptosis-inducing properties in lovo colon cancer cell line. Applied Sciences-Basel Sep 2021, 11, doi:10.3390/app11188594.IF=2.838; Q2
96. Lacatusu I., Iordache T.A., Mihaila M., Mihaiescu D.E., Pop A.L., Badea N. Multifaced role of dual herbal principles loaded-lipid nanocarriers in providing high therapeutic efficacity. Pharmaceutics Sep 2021, 13, doi:10.3390/pharmaceutics13091511.IF=6.525; Q1
95. Bostan M., Mihaila M., Petrica-Matei G.G., Radu N., Hainarosie R., Stefanescu C.D., Roman V., Diaconu C.C. Resveratrol modulation of apoptosis and cell cycle response to cisplatin in head and neck cancer cell lines. International Journal of Molecular Sciences Jun 2021, 22, doi:10.3390/ijms22126322.IF=6.209; Q2
94. Stecoza C.E., Nitulescu G.M., Draghici C., Caproiu M.T., Olaru O.T., Bostan M., Mihaila M. Synthesis and anticancer evaluation of new 1,3,4-oxadiazole derivatives. Pharmaceuticals May 2021, 14, doi:10.3390/ph14050438.IF=5.215; Q1
93. Munteanu A.C., Musat M.G., Mihaila M., Badea M., Olar R., Nitulescu G.M., Radulescu F.S., Brasoveanu L.I., Uivarosi V. New heteroleptic lanthanide complexes as multimodal drugs: Cytotoxicity studies, apoptosis, cell cycle analysis, DNA interactions, and protein binding. Applied Organometallic Chemistry Jan 2021, 35, doi:10.1002/aoc.6062.IF=4.072; Q1
92. Maciuca A.M., Munteanu A.C., Mihaila M., Badea M., Olar R., Nitulescu G.M., Munteanu C.V.A., Bostan M., Uivarosi V. Rare-earth metal complexes of the antibacterial drug oxolinic acid: Synthesis, characterization, DNA/protein binding and cytotoxicity studies. Molecules Nov 2020, 25, doi:10.3390/molecules25225418.IF=4.412; Q3
91. Ioan D.C., Rau I., Kaya M.G.A., Radu N., Bostan M., Zgarian R.G., Tihan G.T., Dinu-Pirvu C.E., Lupuliasa A., Ghica M.V. Ciprofloxacin-collagen-based materials with potential oral surgical applications. Polymers Sep 2020, 12, doi:10.3390/polym12091915.IF=4.329; Q1
90. Bostan M., Petrica-Matei G.G., Radu N., Hainarosie R., Stefanescu C.D., Diaconu C.C., Roman V. The effect of resveratrol or curcumin on head and neck cancer cells sensitivity to the cytotoxic effects of cisplatin. Nutrients Sep 2020, 12, doi:10.3390/nu12092596.IF=5.719; Q1
89. Radu N., Chirvase A.A., Babeanu N., Popa O., Cornea P., Pirvu L., Bostan M., Ciric A., Mathe E., Radu E., Doni M., Constantin M., Raut I., Gurban A.M., Begea M. Study regarding the potential use of a spent microbial biomass in fertilizer manufacturing. Agronomy-Basel Feb 2020, 10, doi:10.3390/agronomy10020299.IF=3.417; Q1
88. Roman V., Radu N., Bostan M., Popa O., Tanasescu C.a.H. Effect of Melaleuca alternifolia bioproduct on acute monocytic leukemia cells line. Molecular Crystals and Liquid Crystals Dec 2019, 695, doi:10.1080/15421406.2020.1723903.IF=0.512; Q4
87. Bostan M., Radu N., Babeanu N., Zaharie M.G., Tanasescu C.a.H. Biological properties of a biomaterial obtained from Syzygium aromaticum. Molecular Crystals and Liquid Crystals Dec 2019, 695, doi:10.1080/15421406.2020.1723905.IF=0.512; Q4
86. Bostan M., Petrica-Matei G.G., Ion G., Radu N., Mihaila M., Hainarosie R., Brasoveanu L.I., Roman V., Constantin C., Neagu M.T. Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by erk1/2 protein kinases. Experimental and Therapeutic Medicine Dec 2019, 18, doi:10.3892/etm.2019.8139.IF=1.785; Q3
85. Caramihai M., Radu N., Bostan M., Ion G., Chirvase A., Constantin M., Doni M., Babeanu N. Fuzzy predictions regarding in vitro behavior of cells line under cytostatic treatment. In Proceedings of the 2019 E-Health and Bioengineering Conference (EHB), Nov 2019,1-5.doi:10.1109/ehb47216.2019.8970088
84. Dumitru M., Gruia M.I., Botezatu A., Mihaila M., Hotnog C.M., Hortopan M., Panait M.E., Anton G., Brasoveanu L.I. Her2 Ile655Val polymorphism, EGFR expression and cellular proliferation in urinary bladder carcinomas. Annals of Oncology Nov 2019, 30, doi:10.1093/annonc/mdz413.078.IF=18.274; Q1
83. Neagu M., Constantin C., Bostan M., Caruntu C., Ignat S.R., Dinescu S., Costache M. Proteomic technology “lens” for epithelial-mesenchymal transition process identification in oncology. Analytical Cellular Pathology Oct 2019, 2019, doi 10.1155/2019/3565970. IF=2.052; Q3
82. Ciocilteu M.V., Podgoreanu P., Delcaru C., Chifiriuc M.C., Manda C.V., Bita A., Popescu M., Amzoiu E., Croitoru O., Bleotu C., Bostan M., Neamtu J. Plga-gentamicin biocomposite materials with potential antimicrobial applications in orthopedics. Farmacia Jul-Aug 2019, 67, 580-586, doi:10.31925/farmacia.2019.4.4..IF=1.607; Q4
81. Lacatusu I., Badea N., Badea G., Mihaila M., Ott C., Stan R., Meghea A. Advanced bioactive lipid nanocarriers loaded with natural and synthetic anti-inflammatory actives. Chemical Engineering Science Jun 2019, 200, doi:10.1016/j.ces.2019.01.044.IF=3.871; Q1
80. Ciulu-Costinescu F., Podgoreanu P., Delcaru C., Simionescu A., Georgescu E.F., Bostan M., Chifiriuc M.C. Antimicrobial assay of a capsaicin – α-cyclodextrin inclusion complex against planktonic and adherent cells. Farmacia May-Jun 2019, 67, doi:10.31925/farmacia.2019.3.18.IF=1.607; Q4
79. Hotnog C.M., Mihaila M., Puiu L., Botezatu A., Roman V., Popescu I.D., Bostan M., Brasoveanu L.I. Modulation of the interplay between p53, ICAM-1 and VEGF in drug-treated LoVo colon cancer cells. Romanian Biotechnological Letters Mar-Apr 2019, 24, doi:10.25083/rbl/24.2/261.270.IF=0.765; Q4
78. Petrica-Matei G.G., Roman V., Mihaila M., Hotnog C.M., Brasoveanu L.I., Bostan M. Role of p38-mitogen-activated protein kinase in modulation of the response to therapy in fadu human pharyngeal carcinoma cell. Romanian Biotechnological Letters Jan-Feb 2019, 24, doi:10.25083/rbl/24.1/118.128. IF=0.765; Q4
77. Munteanu A.C., Badea M., Olar R., Silvestro L., Mihaila M., Brasoveanu L.I., Musat M.G., Andries A., Uivarosi V. Cytotoxicity studies, DNA interaction and protein binding of new al (III), ga (III) and in (III) complexes with 5-hydroxyflavone. Applied Organometallic Chemistry Dec 2018, 32, doi:10.1002/aoc.4579..IF=3.259; Q1
76. Murarasu D., Puiu L., Pitica I.M.A., Mambet C., Mihalcea C.E., Marincas A.M., Cinca S., Brasoveanu L., Diaconu C.C. tp53 somatic mutations and loh profile in colorectal cancer in Romania. Romanian Biotechnological Letters Mar-Apr 2018, 23, IF=0.590; Q4
75. Radu N., Roman V., Bostan M., Voicescu M., Tanasescu C. Bioproduct obtained from probiotic microorganisms consortia-studies regarding the effects generated in vitro on two types of leukemic cell lines. Molecular Crystals and Liquid Crystals Dec 2017, 655, doi:10.1080/15421406.2017.1362311.IF=0.559; Q4
74. Radu N., Roman V., Bostan M., Radu E., Tanasescu C. Influence of some spice food based bioproducts on human monocytic cells line type THP-1. Molecular Crystals and Liquid Crystals Dec 2017, 655, doi:10.1080/15421406.2017.1361307.IF=0.633; Q3
73. Radu N., Roman V., Bostan M., Voicescu M., Tanasescu C. Effects of biomaterials obtained from consortia of probiotic microorganism in submerged biosynthesis on THP1 cells line. Molecular Crystals and Liquid Crystals Dec 2017, 655, doi:10.1080/15421406.2017.1362308.IF=0.633; Q3
72. Lixandru D., Alexandru P., Mihai A., Rosca A., Ionescu-Tîrgoviste C., Brasoveanu L.I., Manuel-Y-Keenoy B. Decreased paraoxonase 2 enzymatic activity in monocyte/macrophages cells. A comparative in vivo and in vitro study for diabetes. Free Radical Research Jun 2017, 51,604-615, doi: 10.1080/10715762.2017.1344983.IF=6.838; Q1
71. Badea G., Badea N., Brasoveanu L.I., Mihaila M., Stan R., Istrati D., Balaci T., Lacatusu I. Naringenin improves the sunscreen performance of vegetable nanocarriers. New Journal of Chemistry Jan 2017, 41, doi:10.1039/c6nj02318e.IF=3.201; Q2
70. Bostan M., Mihaila M., Hotnog C., Bleotu C., Anton G., Roman V., Brasoveanu L.I. Modulation of apoptosis in colon cancer cells by bioactive compounds. Colorectal Cancer – From Pathogenesis to Treatment, Sep 2016, doi:10.5772/63382.
69. Lacatusu I., Badea N., Badea G., Brasoveanu L., Stan R., Ott C., Oprea O., Meghea A. ivy leaves extract based – lipid nanocarriers and their bioefficacy on antioxidant and antitumor activities. Rsc Advances Aug 2016, 6, doi:10.1039/c6ra12016d.IF=3.108; Q2
68. Radu N., Roman V., Tanasescu C. Biomaterials obtained from probiotic consortia of microorganisms. Potential applications in regenerative medicine. Molecular Crystals and Liquid Crystals May 2016, 628, doi:10.1080/15421406.2015.1137686.IF=0.571;N/A
67. Hotnog D., Mihaila M., Botezatu A., Matei G.G., Hotnog C., Anton G., Bostan M., Brasoveanu L.I. Genistein potentiates the apoptotic effect of 5-fluorouracyl in colon cancer cell lines. Romanian Biotechnological Letters Nov-Dec 2013, 18, 8751-8760.IF=0.351;Q4
66. Mihaila M., Bostan M., Hotnog D., Ferdes M., Brasoveanu L.I. Real-time analysis of quercetin, resveratrol and/or doxorubicin effects in mcf-7 cells. Romanian Biotechnological Letters Mar-Apr 2013, 18, 8106-8114.IF=0.351;Q4
65. Dumitru M., Gruia M.I., Hortopan M.G., Vasilescu M.M., Mihaila M., Hotnog C.M., Brasoveanu L.I. Her2 gene amplification, phosphorylated-Her2, Egfr expression and DNA ploidy in urinary bladder carcinomas. Febs Journal Sep 2012, 279, 319-320..IF=2.250;Q2.
64. Brasoveanu L.I., Hotnog D., Hotnog C., Bostan M., Mihaila M. Modulation of genistein- and resveratrol-induced apoptosis and cell proliferation in colon cancer cells. European Journal of Cancer Jul 2012, 48, S267-S268, doi:10.1016/s0959-8049(12)71713-6.IF=5.061;Q1
63. Iova A., Bumbea H., Roman V., Vladareanu A.M., Cazaceanu O., Enache C., Begu M. CD200 in diagnosis of chronic lymphoproliferative disorders- a study of 122 patients. Haematologica Jul 2012, 97, 298-298.
62. Mihaila M., Hotnog C., Dina I., Hotnog D., Brasoveanu L.I. Modulation of cell signalling mechanisms in colon cancer cells. Febs Journal Jun 2011, 278, 362-362.IF=3.790;Q2
61. Brasoveanu L.I., Mihaila M., Dina I., Hotnog C., Puiu L. P53 and apoptosis could be modulated by natural compounds in colon cancer cells. Febs Journal Jun 2011, 278, 344-344.IF=3.790;Q2
60. Mihaila M., Hotnog C., Theodor V., Brasoveanu L.I. Effect of stimuli treatment on cell signalling mechanisms associated to oral cancers. Scandinavian Journal of Immunology Jun 2010, 71, 502-502.IF=1.935;Q4
59. Mihaila M., Hotnog C., Theodor V., Brasoveanu L. Effect of stimuli treatment on proliferation, apoptosis and cell signalling mechanisms associated to oral cancers. Ejc Supplements Jun 2010, 8, doi:10.1016/s1359-6349(10)71115-0.IF=9.386;Q1
58. Brasoveanu L.I., Hotnog C., Mihaila M., Puiu L. Expression of cell adhesion molecules on mdr-1 positive stimuli treated breast tumour cells. Ejc Supplements Jun 2010, 8, doi:10.1016/s1359-6349(10)71114-9.IF=9.386;Q1
57. Hotnog D., Roman V. Mitochondrial apoptotic molecules and genistein. Ejc Supplements Jun 2010, 8, doi:10.1016/s1359-6349(10)71585-8.IF=9.386;Q1
56. Hotnog C., Mihaila M., Brasoveanu L.I. Gene expression analysis of tumour markers associated to apoptosis and proliferation in head and neck cancer. Ejc Supplements Jun 2010, 8, doi:10.1016/s1359-6349(10)71113-7.IF=9.386;Q1
55. Anton G., Brasoveanu L.I., Socolov D., Botezatu A., Anton M., Goia C.D., Iancu I.V., Cucu N. Epigenetic regulation to anti-cancer drugs in HPV positive cell lines. Ejc Supplements Jun 2010, 8, doi:10.1016/s1359-6349(10)71083-1.IF=9.386;Q1
54. Bumbea H., Vladareanu A.M., Radesi S., Vintilescu A., Roman V., Ciufu C., Hotnog D., Arama V., Onisai M., Popov V.M., Baluta C., Cazaceanu O., Voican I., Cisleanu D., Marinescu C., Arama S., Rafila A., Streinu-Cercel A., Nicolescu A., Gaman M., Ichim A., Begu M. Viral infectious in chronic lymphoproliferative disorders-immunophenotypic changes. Haematologica-the Hematology Journal Jun 2010, 95, 612-612.
53. Bostan M., Matei G.G., Manu D., Brasoveanu L.I. Induction of apoptosis by cisplatin and its effect on cell cycle changes in laryngeal cancer. Scandinavian Journal of Immunology Jun 2010, 71, 500-501.IF=1.935;Q4
52. Bumbea H., Radesi S., Vladareanu A.M., Roman V., Vintilescu A. Complex immunophenotypic changes as prognosis panel in chronic lymphocytic leukemia. Clinical Lymphoma & Myeloma Dec 2009, 9, doi:10.3816/CLM.2009.n.099.IF=1.130;Q4
51. Hirt M., Hotnog D., Hotnog C., Puil L., Brasoveanu L.I. Effect of stimuli treatment on cell signalling mechanisms associated to colorectal cell lines. In Proceedings of the 2nd European Congress of Immunology (ECI), Sep 2009, 391-+.
50. Brasoveann L.L., Hirt M., Matel G., Bostan M., Puiu L. Stimuli modulation of apoptosis and proliferation through cell cycle phases hi colon cancer cell lines. In Proceedings of the 2nd European Congress of Immunology (ECI), Sep 2009, 127-+.
49. Bostan M., Matei G.G., Manu D.A., Theodor V., Brasoveanu L.I. Analysis of the effects after resveratrol treatment on cell cycle and apoptosis in tumor laryngeal cells. In Proceedings of the 2nd European Congress of Immunology (ECI), Sep 2009, 387-+.
48. Roman T., Hotnog l D., Maglas C., Bumbea H. Genistein-induced apoptosis on Mec1 cell line. Haematologica-the Hematology Journal Jun 2009, 94, 598-598.
47. Niculae D., Lungu V., Brasoveanu L., Savu D., Iliescu M. In vitro biological evaluation of 188re-anti-vegf-mab and 188re-anti-muc1. Journal of Labelled Compounds & Radiopharmaceuticals Jun 2009, 52, 258-259.IF=0.689;Q4
46. Brasoveanu L.I., Anton G., Hirt M., Stoian M. Modulation by stimuli treatment of cam expression, proliferation and apoptosis associated to cervix tumor cells. Anticancer Research Sep-Oct 2008, 28, 3219-3219.IF=1.394;Q4
45. Anton G., Brasovearu L.I., Botezatu A., Lulial L., Mihai S., Cucu N. Saha anticancer activity through derepression effect on critical genes in HPV cell lines. Anticancer Research Sep-Oct 2008, 28, 3198-3199. IF=1.394;Q4
44. Roman V., Hotnog D., Maglas C., Brasoveanu L.I. Effects of mycotoxins on apoptosis of human immune system. Ejc Supplements Jul 2008, 6, doi:10.1016/s1359-6349(08)71696-3. IF=3.406;Q2
43. Brasoveanu L.I., Hotnog C., Roman V., Hirt M., Bostan M., Cinca S., Puiu L. Effect of stimuli treatment on proliferation and apoptosis of tumor cells. Ejc Supplements Jul 2008, 6, doi:10.1016/s1359-6349(08)71698-7. IF=3.406;Q2
42. Lixandru D., Heytens E., Brasoveanu L.I., Manuel-Y-Keenoy B. Triglyceride rich lipoproteins reverse the alterations in respiratory burst and pon2 activity in serum-deprived cells from the monocyte line U937. Free Radical Research Jul 2008, 42, S76-S76.IF=2.826;Q2
41. Hirt M., Hotnog C., Cimpean A., Puiu L., Brasoveanu L.I. Modulation by oncolitical treatment associated with natural compounds on proliferation and apoptosis of breast tumor cells. Febs Journal Jun 2008, 275, 259-259.IF=3.139;Q2
40. Brasoveanu L.I., Hirt M., Hotnog C., Gruia M.I., Puiu L. Biomarkers in radioimmunotherapy of breast and ovarian cancers. Febs Journal Jun 2008, 275, 257-257.IF=3.139;Q2
39. Ionesti M.C., Matei G., Hirt M., Bostan M., Puiu L., Brasoveanu L.I. Correlation analysis between expression and functional roles of cam on doxorubicin treated tumor cells. Febs Journal Jul 2007, 274, 264-264.IF=3.396;Q2
38. Hotnog D., Brasoveanu L.I., Ionesti C.M., Roman V. Role of flavonoids in cancer immunotherapy. Febs Journal Jul 2007, 274, 159-159.IF=3.396;Q2
37. Brasoveanu L.I., Ionesti M.C., Hotnog D., Hirt M., Bostan M., Puiu L. Modulation by stimuli treatment of proliferation, cell cycle phases and apoptosis of tumor cells. Febs Journal Jul 2007, 274, 177-177. IF=3.396;Q2
36. Alexandru V., Petrusca D.N., Gille E. Investigation of pro-apoptotic activity of Equisetum arvense l. Water extract on human leukemia U937 cells. Romanian Biotechnological Letters Mar-Apr 2007, 12, 3139-3147.
35. Hotnog D., Roman V., Brasoveanu L.I., Billard C., Kolb J.P. Resveratrol and mitochondrial pathway of apoptosis. Febs Journal Jun 2006, 273, 125-125.IF=3.033;Q2
34. Brasoveanu L.I., Hotnog D., Simioana M.D., Puiu L., Constantin M.C. Tumor markers of potential clinical use in radioimmunotherapy. Febs Journal Jun 2006, 273, 276-276.IF=3.033;Q2
33. Puiu L., Constantin M.C., Simioana M.D., Hotnog D., Diaconu C.C., Brasoveanu L.I. Modulation of drug-induced apoptosis in breast cancer cell lines. Anticancer Research Sep-Oct 2004, 24, 3607-3608.IF=1.395;Q3
32. Brasoveanu L.I., Simioana M.D., Hotnog D., Puiu L., Condrea I., Constantin M.C., Gruia M.I. Mechanisms of tumor resistance to anti-Muc-1 treatment involving complement regulatory proteins. Anticancer Research Sep-Oct 2004, 24, 3443-3444.IF=1.395;Q3
31. Mota G., Moldovan I., Calugaru A., Hirt M., Kozma E., Galatiuc C., Brasoveanu L., Boltz-Nitulescu G. Interaction of human immunoglobulin G with CD16 on natural killer cells: Ligand clearance, fcγriiia turnover and effects of metalloproteinases on fcγriiia-mediated binding, signal transduction and killing. Scandinavian Journal of Immunology Mar 2004, 59, doi:10.1111/j.0300-9475.2004.01398.x.IF=1.912;Q3
30. Diaconu C.C., Bleotu C., Chivu M., Alexiu I., Petrusca D., Anton G., Achim R., Ruta S.M., Cernescu C. The development of larger cells that spontaneously escape senescence – a step during the immortalization of a human cancer cell line. Journal of Cellular and Molecular Medicine Jan-Mar 2004, 8, doi:10.1111/j.1582-4934.2004.tb00263.x.IF=2.153;N/A
29. Bostan M., Galatiuc C., Hirt M., Constantin M.C., Brasoveanu L.I., Iordachescu D. Phospholipase a(2) modulates respiratory burst developed by neutrophils in patients with rheumatoid arthritis. Journal of Cellular and Molecular Medicine Jan-Mar 2003, 7, doi:10.1111/j.1582-4934.2003.tb00203.x.IF=1.694;N/A
28. Mota G., Manciulea M., Cosma E., Popescu I., Hirt M., Jensen-Jarolim E., Calugaru A., Galatiuc C., Regalia T., Tamandl D., Spittler A., Boltz-Nitulescu G. Human nk cells express fc receptors for IgA which mediate signal transduction and target cell killing. European Journal of Immunology Aug 2003, 33, doi:10.1002/eji.200323534.IF=4.536;Q1
27. Prechl J., Baiu D.C., Horváth A., Erdei A. Modeling the presentation of c3d-coated antigen by b lymphocytes:: Enhancement by cr1/2-bcr co-ligation is selective for the co-ligating antigen. International Immunology Mar 2002, 14, doi:10.1093/intimm/14.3.241.IF=3.595;Q1
26. Roman V., Mentz F., Dugas N., Dugas B., Sigaux F., Kolb J.P. Apoptotic process modulated by nitric oxide in chronic b-cell lymphocytic leukemia. In Proceedings of the Conference of the NATO Advanced Study Institute on Nitric Oxide, Sep 2000, 188-189.
25. Popescu I., Hirt M., Calugaru A., Balu D., Manciulea M., Metes D., Morel P., Herberman R., Sulica A. Cross-talk between C gamma RIIA, and C gamma RIIC an human natural killer cells. European Journal of Cancer Sep 1999, 35, S106, doi:10.1016/s0959-8049(99)80805-3..IF=2.537;Q2
24. Pinti M., Pedrazzi J., Benatti F., Sorrentino V., Nuzzo C., Cavazzuti V., Biswas P., Petrusca D.N., Mussini C., De Rienzo B., Cossarizza A. Differential down-regulation of CD95 or CD95l in chronically HIV-infected cells of monocytic or lymphocytic origin: Cellular studies and molecular analysis by quantitative competitive rt-pcr. Febs Letters Sep 1999, 458, doi:10.1016/s0014-5793(99)01131-x.IF=3.720;Q1
23. Metes D., Manciulea M., Pretrusca D., Rabinowich H., Ernst L.K., Popescu L., Calugaru A., Sulica A., Chambers W.H., Herberman R.B., Morel P.A. Ligand binding specificities and signal transduction pathways of Fcγ receptor IIC isoforms:: The CD32 isoforms expressed by human NK cells. European Journal of Immunology Sep 1999, 29, doi:10.1002/(sici)1521-4141(199909)29:09<2842::aid-immu2842>3.0.co;2-5.IF=5.635;Q1
22. Prechl J., Tchorbanov A., Horváth A., Baiu D.C., Hazenbos W., Rajnavölgyi E., Kurucz I., Capel P.J.A., Erdei A. Targeting of influenza epitopes to murine cr1/cr2 using single-chain antibodies. Immunopharmacology May 1999, 42, doi:10.1016/s0162-3109(99)00025-9.
21. Moldovan I., Galon J., Maridonneau-Parini I., Roman S.R., Mathiot C., Fridman W.H., Sautès-Fridman C. Regulation of production of soluble fcγ receptors type iii in normal and pathological conditions. Immunology Letters May 1999, 68, doi:10.1016/s0165-2478(99)00041-3.IF=1.494;Q3
20. Roman S., Petrusca D., Moldovan I., Paraoan M., Petrescu A., Damian D., Noica N., Sulica A. Evaluation of apoptosis of tumor and of apparently normal cells in human renal carcinoma. Immunology Letters Mar 1999, 67, doi:10.1016/s0165-2478(98)00110-2.IF=1.494;Q3
19. Baiu D.C., Prechl J., Tchorbanov A., Molina H.D., Erdei A., Sulica A., Capel P.J.A., Hazenbos W.L.W. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and fc receptors. Journal of Immunology Mar 1999, 162, 3125-3130.IF=7.145;Q1
18. Hirt M., Cheta D., Popescu I., Sulica A., Manciulea M. Changes in fcγriiia signalling induced by nonenzymatic glucosilation of igg. Diabetologia Aug 1998, 41, A102-A102..IF=4.986;Q1
17. Galon J., Moldovan I., Galinha A., Provost-Marloie M.A., Kaudewitz H., Roman-Roman S., Fridman W.H., Sautès C. Identification of the cleavage site involved in production of plasma soluble fc gamma receptor type III (CD16). European Journal of Immunology Jul 1998, 28, doi:10.1002/(sici)1521-4141(199807)28:07<2101::aid-immu2101>3.0.co;2-w.IF=5.438;Q1
16. Metes D., Ernst L.K., Chambers W.H., Sulica A., Herberman R.B., Morel P.A. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the fcγriic gene. Blood Apr 1998, 91, doi:10.1182/blood.V91.7.2369.2369_2369_2380.IF=8.372;Q1
15. Metes D., Manciulea M., Rabinowich H., Sulica A., Ernst L.K., Herberman R.B., Morel P.A. Functional analysis of Fc gamma RIIC expressed in Jurkat transfectants. Faseb Journal Mar 1998, 12, A907-A907.IF=13.861;Q1
14. Metes D., Ernst L.K., Chambers W.H., Sulica A., Herberman R.B., Morel P.A. Novel fc gamma riic isoforms expressed by human NK cells. Journal of Allergy and Clinical Immunology Jan 1997, 99, 1890-1890.IF=3.769;Q1
13. Sulica A., Herberman R.B. Cytophilic immunoglobulins revisited via natural killer cells. Faseb Journal Nov 1996, 10, doi:10.1096/fasebj.10.13.8940295.
12. Medesan C., Radu C., Kim J.K., Ghetie V., Ward E.S. Localization of the site of the igg molecule that regulates maternofetal transmission in mice. European Journal of Immunology Oct 1996, 26, 2533-2536, doi:10.1002/eji.1830261038.
11. Rabinowich H., Manciulea M., Metes D., Sulica A., Herberman R.B., Corey S.J., Whiteside T.L. Physical and functional association of fc mu receptor on human natural killer cells with the zeta- and fc epsilon ri gamma-chains and with src family protein tyrosine kinases. Journal of Immunology Aug 1996, 157, 1485-1491.
10. Sulica A., Metes D., Gherman M., Whiteside T.L., Herberman R.B. Divergent effects of Fc gamma RIIIA ligands on the functional activities of human natural killer cells in vitro. European Journal of Immunology Jun 1996, 26, 1199-1203, doi:10.1002/eji.1830260602.
9. Metes D., Ernst L., Chambers W., Sulica A., Herberman R.B., Morel P.A. Fc gamma riic isoforms expressed by human NK cells. Faseb Journal Apr 1996, 10, 1087-1087.
8. Manciulea M., Rabinowich H., Sulica A., Lin W.C., Whiteside T.L., Deleo A., Herberman R.B., Corey S.J. Divergent phosphotyrosine signaling via Fc gamma RIIIA on human NK cells. Cellular Immunology Jan 1996, 167, doi:10.1006/cimm.1996.0008.
7. Galatiuc C., Gherman M., Metes D., Sulica A., Deleo A., Whiteside T.L., Herberman R.B. Natural-killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies. Cellular Immunology Jul 1995, 163, doi:10.1006/cimm.1995.1113.
6. Metes D., Chambers W., Sulica A., Herberman R., Morel P.A. Molecular characterization of CD32 isoforms in human NK cells. Faseb Journal Mar 1995, 9, A218-A218.
5. Metes D., Galatiuc C., Moldovan I., Morel P.A., Chambers W.H., Deleo A.B., Rabinowich H., Schall R., Whiteside T.L., Sulica A., Herberman R.B. Expression and function of Fc-gamma-RII on human natural-killer-cells. Natural Immunity Nov-Dec 1994, 13, 289-300.
4. Metes D., Sulica A., Rabinowich H., Lin W., Chambers W., Morel P., Whiteside T.L., Corey S.J., Herberman R.B., Manciulea M. Activation of tyrosine kinases upon cross-linking of Fc-gamma-RII on human NK cells. Faseb Journal Mar 1994, 8, A987-A987.
3. Manciulea M., Rabinowich H., Metes D., Lin W.C., Sulica A., Herberman R.B., Whiteside T.L., Corey S.J. Activation of protein-tyrosine kinases in human NK cells by triggering via Fc-mu receptor. Faseb Journal Mar 1994, 8, A988-A988.
2. Manciulea M., Sulica A., Rabinovich H., Lin W., Whiteside T., Deleo A., Herberman R., Corey S. Phosphotyrosine proteins, PI 3-kinase and calcium changes distinguish activating and inhibitory pathways via Fc-gamma-riiia in human NK cells. Blood Nov 1993, 82, A247-A247.
1. Pricop L., Rabinowich H., Morel P.A., Sulica A., Whiteside T.L., Herberman R.B. Characterization of the Fc-mu-receptor on human natural-killer-cells – interaction with its physiological ligand, human normal IgM, specificity of binding, and functional-effects. Journal of Immunology Sep 1993, 151, 3018-3029.
